La Merie
La Merie Publishing - Biologics Blog

STUTTGART, Germany I June 19, 2018 I La Merie Publishing released the results of an independent search for and evaluation of PD-1 and PD-L1 immune checkpoint inhibitors in preclinical and clinical development by pharmaceutical companies.

This Competitive Intelligence report analyzes the competitive field of PD-1 and PD-L1 Immune Checkpoint Inhibitors as of June 2018 in a tabulated format with structured listings of industry-relevant data. The report describes the lead indications of each unique molecule in the most advanced R&D stage separately for regulated and less regulated markets and differentiates between specific and bi- or multispecific molecules.

Published in Blog